Airway diseases
Interstitial lung diseases
Pulmonary vascular diseases
Poster discussion
Translational aspects of idiopathic pulmonary fibrosis
Methods :
Physiology, Cell and molecular biology
LSC - 2019 - Inflammasomes’ activation in alveolar macrophages and peripheral blood mononuclear cells in fibrotic Interstitial Lung Diseases
A. Trachalaki(London, United Kingdom)
COI
1
Potential clinical utility of MUC5B and TOLLIP single nucleotide polymorphisms (SNP) in in the management of patients with IPF.
F. Bonella(Essen, Germany)
COI
2
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice
K. Kagawa(Tokushima, Japan)
COI
4
Arsenic trioxyde inhibits the functions on lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
A. Joannes(RENNES, France)
COI
5
IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF
S. Seiwert(Seattle, United States)
COI
6
The effect of mast cell stabilisation in a large animal model of pulmonary fibrosis
S. Vithana Dewage( Melbourne (VIC), Australia)
COI
7
Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis
K. Roach(Leicester (Leicestershire), United Kingdom)
COI
8
Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model
H. Zhou(Tianjin (Tianjin), China)
COI
9
TGFß1-induces resistance to apoptosis in human lung myofibroblasts via TRPA1 downregulation
H. Virk(Leicester (Leicestershire), United Kingdom)
COI
10
Autophagy and senescence are activated mechanisms in idiopathic or autoimmunity caused usual interstitial pneumonia
H. Popper(Graz, Austria)
COI
11
Oleanolic acid acetate ameliorates bleomycin-induced pulmonary fibrosis through inhibition of epithelial-mesenchymal transition
H. Kim(Iksan-si (Jeollabuk-do), Republic of Korea)
COI
12
Defective surfactant biosynthesis and ultrastructural abnormalities of alveolar type 2 cells in pulmonary fibrosis of conditional Nedd4-2mice
D. Leitz(Berlin, Germany)
COI
13
Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis.
N. Chandran(Graz, Austria)
COI
14
LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation
B. Murphy(Pennington , United States)
COI
15
Role of MUC4 in idiopathic pulmonary fibrosis
B. Ballester Llobell(Burjassot (Valencia), Spain)
COI
16
In vivo blockade of KCa3.1 ion channel alleviates ER stress in type II alveolar epithelial cells and macrophages in pulmonary fibrosis
K. Perera(Melbourne (VIC), Australia)
COI
17
Tankyrase(TNKS) inhibiting autophagy promotes the TGF-ß induced EMT process in vitro and Bleomycin(BLM) induced pulmonary fibrosis in rats
L. Liu(Chengdu (Sichuan), China)
COI
18
. . .
